This triplet combination is safe and effective in patients with relapsed/refractory multiple myeloma... The use of the CD38-directed monoclonal antibody daratumumab was associated with ocular events... The ORR was 96%, including 92% at the level of VGPR, and the MRD negativity rate was 62%... Among 37 evaluable patients, the ORR was 78%, and 27 patients had a VGPR or better... Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, shares his thoughts. Dr. Laubach, from Dana-Farber Cancer Institute, reviews follow-up data from the phase II GRIFFIN trial.